Regulatory Affairs Management
Leading regulatory affairs managers can act as a seamless extension of Sponsor regulatory teams.
Thanks to MMS and especially the team… we reset the relationship that we have with the FDA and moved our lead asset forward through to getting our clinical trial started.
MMS regulatory strategy experts provide consulting and can be assigned as the product lead or a lead for a specific submission type, if needed.
MMS Regulatory Affairs Managers are a true extension of Sponsor regulatory affairs teams. These knowledgeable, experienced resources are assigned to specific products and applications and work with Sponsor teams to execute regulatory activities and facilitate optimal progress and development.
Our Regulatory Affairs Managers are responsible to support the following:
- Communication of regulatory requirements and provision of status updates to stakeholders in the Sponsor company
- Development of Module 1 content required for global health authority interactions, including the FDA, EMA, and others
- Review of required regulatory documentation and files created by other functional lines
- Representation to and interactions with global health authorities on behalf of the Sponsor
Leads the team in the preparation and execution of large and/or complex dossiers
For more information on submissions support, see here.
Regulatory Affairs Managers and Strategists regularly create regional, Module 1 documentation and provide the Sponsor team with expert guidance on the content and format needed to support key interactions with global health authorities.
Suggested For You
webinar
April 30th, 2025
Advancing Clinical Development with Innovative Trial Design and Regulatory Strategies
perspectives
February 13th, 2025
Helping European Drug Development Companies Succeed in the US Market
webinar
March 5th, 2025
Overcoming NDA/BLA Submission Challenges: Practical Strategies for Success
perspectives
November 12th, 2024
REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar
news
November 7th, 2024
MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance
perspectives
September 30th, 2024
The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry
perspectives
September 11th, 2024
From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs
webinar
September 26th, 2024
Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance
regulatory intelligence
August 27th, 2024
Recent Guidance on Diversity Action Planning
regulatory intelligence
August 26th, 2024
Oncology Programs at the FDA
regulatory intelligence
August 26th, 2024
Three Key Take Reflections on the Recent Donanemab Approval
webinar
September 12th, 2024
No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology